{"issuance_frequency":"","notes_translated":{"fr":"Les exigences modifiées concernant les médicaments contre la COVID-19 permettent de soumettre des présentations en continu (paragraphe C.08.002(2.3) du Règlement sur les aliments et drogues). Avant de déposer une présentation pour un examen en continu, les promoteurs d'essais cliniques sont censés avoir recueilli un certain niveau de preuves sur l'innocuité, la qualité et l'efficacité de leur vaccin. ","en":"Modified requirements for COVID-19 drugs allow for the filing of rolling submissions (section C.08.002(2.3) of Canada's Food and Drug Regulations). Before filing a submission for a rolling review, sponsors of clinical trials are expected to have gathered a certain level of evidence on the safety, quality and efficacy of their vaccine. "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"f754a358-811b-4047-b898-a1b43f2458fd","metadata_created":"2021-07-27T14:01:54.883580","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-27T14:01:54.883586","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-27","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["coronavirus","COVID-19","pandémie","médicaments","médicaments","vaccins","autorisation de mise en marché","licence","importation ou vente","vaccin COVID-19","soumissions continues","exigences non cliniques","exigences cliniques"],"en":["coronavirus","COVID-19","pandemic","drugs","medications","vaccines","market authorization","licensing","importing or selling","COVID-19 vaccine","rolling submissions","non-clinical requirements","clinical requirements"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Lignes directrices sur les exigences relatives aux autorisations de mise en marché des vaccins contre la COVID-19 : Présentations en continu, exigences non cliniques et cliniques","en":"Guidance for market authorization requirements for COVID-19 vaccines: Rolling submissions, non-clinical and clinical requirements"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"f754a358-811b-4047-b898-a1b43f2458fd","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"53763716-c541-4172-abb9-7e806014dfb1","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les exigences relatives aux autorisations de mise en marché des vaccins contre la COVID-19 : Présentations en continu, exigences non cliniques et cliniques","en":"Guidance for market authorization requirements for COVID-19 vaccines: Rolling submissions, non-clinical and clinical requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance for market authorization requirements for COVID-19 vaccines: Rolling submissions, non-clinical and clinical requirements","language":["en"],"created":"2021-07-27T14:01:54.967818","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/guidance-market-authorization-vaccines/rolling-submissions-non-clinical-requirements.html","last_modified":null,"position":0,"revision_id":"3f60ce66-4b30-4859-9606-f5359c07da11","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"f754a358-811b-4047-b898-a1b43f2458fd","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c33afe0b-46b5-4937-9bf0-d059c058cad5","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les exigences relatives aux autorisations de mise en marché des vaccins contre la COVID-19 : Présentations en continu, exigences non cliniques et cliniques","en":"Guidance for market authorization requirements for COVID-19 vaccines: Rolling submissions, non-clinical and clinical requirements"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance for market authorization requirements for COVID-19 vaccines: Rolling submissions, non-clinical and clinical requirements","language":["fr"],"created":"2021-07-27T14:01:54.967825","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/ligne-directrices-autorisations-mise-marche-vaccins/presentations-continu-exigences-non-cliniques.html","last_modified":null,"position":1,"revision_id":"3f60ce66-4b30-4859-9606-f5359c07da11","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-03-30 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"f754a358-811b-4047-b898-a1b43f2458fd","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"Modified requirements for COVID-19 drugs allow for the filing of rolling submissions (section C.08.002(2.3) of Canada's Food and Drug Regulations). Before filing a submission for a rolling review, sponsors of clinical trials are expected to have gathered a certain level of evidence on the safety, quality and efficacy of their vaccine. ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance for market authorization requirements for COVID-19 vaccines: Rolling submissions, non-clinical and clinical requirements","revision_id":"3f60ce66-4b30-4859-9606-f5359c07da11"}